• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (24)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Pain  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Intern Med. 2004;164:1243-1246.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The Celecoxib Long-term Arthritis Safety Study (CLASS) evaluated the adverse gastrointestinal (GI) effects caused by the use of the selective cyclooxygenase 2 (COX-2) drug celecoxib and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with osteoarthritis and rheumatoid arthritis.¹ The study found no significant difference in the GI ulcer complication rate (ie, bleeding, perforation, or obstruction in the GI tract) between celecoxib and nonselective NSAIDs. The authors attributed this finding to a higher-than-anticipated aspirin comedication rate of 21% among study participants, a rate almost double that of previous clinical trial experience. Since usage patterns in clinical trials and routine clinical practice often differ, the purpose of the present study was to estimate aspirin comedication rates among long-term COX-2 users. To provide a thorough description of over-the-counter (OTC) NSAID and pain reliever use, we also examine comedication with 2 other OTC NSAIDs (ie, ibuprofen and naproxen sodium) and another commonly used OTC . . . [Full Text of this Article]

Methods


Results

Comment
Emily R. Cox, PhD; Mark Frisse, MD; Andrew Behm, PharmD; Kathleen A. Fairman, MA
Maryland Heights, Mo

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
Bhatt et al.
J Am Coll Cardiol 2008;52:1502-1517.
FULL TEXT  

ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
Writing Committee Members et al.
Circulation 2008;118:1894-1909.
FULL TEXT  

Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe?
Waksman et al.
The Annals of Pharmacotherapy 2007;41:1163-1173.
ABSTRACT | FULL TEXT  

Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study
Rahme et al.
Rheumatology (Oxford) 2007;46:265-272.
ABSTRACT | FULL TEXT  

Arthritis Medicines and Cardiovascular Events--"House of Coxibs"
Topol
JAMA 2005;293:366-368.
FULL TEXT